» Articles » PMID: 15770205

A Prospective, Randomised Study to Compare Two Palliative Radiotherapy Schedules for Non-small-cell Lung Cancer (NSCLC)

Overview
Journal Br J Cancer
Specialty Oncology
Date 2005 Mar 17
PMID 15770205
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

A prospective randomised study compared two palliative radiotherapy schedules for inoperable symptomatic non-small-cell lung cancer (NSCLC). After stratification, 100 patients were randomly assigned to 20 Gy/5 fractions (fr)/5 days (arm A) or 16 Gy/2 fr/day 1 and 8 (arm B). There were 90 men and 10 women aged 47-81 years (mean 66), performance status 1-4 (median 2). The major clinical characteristics and incidence and degree of initial disease-related symptoms were similar in both groups. Treatment effects were assessed using patient's chart, doctor's scoring of symptomatic change and chest X-ray. Study end points included degree and duration of symptomatic relief, treatment side effects, objective response rates and overall survival. A total of 55 patients were assigned to arm A and 45 to arm B. In all, 98 patients received assigned treatment, whereas two patients died before its termination. Treatment tolerance was good and did not differ between study arms. No significant differences between study arms were observed in the degree of relief of all analysed symptoms. Overall survival time differed significantly in favour of arm B (median 8.0 vs 5.3 months; P=0.016). Both irradiation schedules provided comparable, effective palliation of tumour-related symptoms. The improved overall survival and treatment convenience of 2-fraction schedule suggest its usefulness in the routine management of symptomatic inoperable NSCLC.

Citing Articles

Descriptors and factors affecting patients' symptom experiences for symptom self-management throughout palliative radiotherapy for advanced lung cancer: A systematic review.

Thanthong S, Kotronoulas G, Johnston B Asia Pac J Oncol Nurs. 2024; 11(10):100577.

PMID: 39391367 PMC: 11466633. DOI: 10.1016/j.apjon.2024.100577.


Palliative Thoracic Radiotherapy in the Era of Modern Cancer Care for NSCLC.

Kepka L Cancers (Basel). 2024; 16(17).

PMID: 39272876 PMC: 11394239. DOI: 10.3390/cancers16173018.


Comparison between 1-week and 2-week palliative radiotherapy courses for superior vena cava syndrome.

Park J, Lee J Radiat Oncol J. 2023; 41(3):178-185.

PMID: 37793627 PMC: 10556839. DOI: 10.3857/roj.2023.00626.


Palliative extracranial radiotherapy in patients receiving immunotherapy for non-small cell lung cancer: a narrative review.

Kepka L Transl Cancer Res. 2023; 12(1):163-176.

PMID: 36760380 PMC: 9906063. DOI: 10.21037/tcr-22-1969.


Use and Reporting of Patient-Reported Outcomes in Trials of Palliative Radiotherapy: A Systematic Review.

Fabian A, Domschikowski J, Letsch A, Schmalz C, Freitag-Wolf S, Dunst J JAMA Netw Open. 2022; 5(9):e2231930.

PMID: 36136335 PMC: 9500555. DOI: 10.1001/jamanetworkopen.2022.31930.


References
1.
ROSWIT B, PATNO M, Rapp R, Veinbergs A, Feder B, Stuhlbarg J . The survival of patients with inoperable lung cancer: a large-scale randomized study of radiation therapy versus placebo. Radiology. 1968; 90(4):688-97. DOI: 10.1148/90.4.688. View

2.
. Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer. 1991; 63(2):265-70. PMC: 1971762. DOI: 10.1038/bjc.1991.62. View

3.
Macbeth F, Bolger J, Hopwood P, Bleehen N, Cartmell J, Girling D . Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol (R Coll Radiol). 1996; 8(3):167-75. DOI: 10.1016/s0936-6555(96)80041-0. View

4.
Abratt R, Shepherd L, Salton D . Palliative radiation for stage 3 non-small cell lung cancer--a prospective study of two moderately high dose regimens. Lung Cancer. 1995; 13(2):137-43. DOI: 10.1016/0169-5002(95)00487-4. View

5.
Cross C, Berman S, Buswell L, Johnson B, Baldini E . Prospective study of palliative hypofractionated radiotherapy (8.5 Gy x 2) for patients with symptomatic non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004; 58(4):1098-105. DOI: 10.1016/j.ijrobp.2003.08.005. View